Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1127.44% is 94% above its 3-year average of -20232.66%, near the high end of its 3-year range (-91050.00%–-31.49%).
192.78% below its 12-month average of -385.07%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -124.11%.
EBITDA MARGIN
-1127.44%
EBITDA MARGIN AVG TTM
-385.07%
EBITDA MARGIN AVG 3Y
-20232.66%
EBITDA MARGIN AVG 5Y
-20232.66%
EBITDA MARGIN AVG 10Y
-9031.46%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-192.78%
CURRENT VS 3Y AVG
+94.43%
CURRENT VS 5Y AVG
+94.43%
CURRENT VS 10Y AVG
+87.52%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Bio Green Med Solution, Inc.
Market Cap
$4.79M
EBITDA Margin
-1127.44%
TTM Avg
-385.07%
3Y Avg
-20232.66%
5Y Avg
-20232.66%
Market Cap
$4.96M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$4.99M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$5.21M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio Green Med Solution, Inc. (BGMS) | $4.79M | -1127.44% | -385.07% | -20232.66% | -20232.66% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -8.85% | 9.13% | 18.32% | 18.32% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| Imunon, Inc. (IMNN)vs › | $5.21M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
Gross Margin
19.3%
EBITDA Margin
-1127.4%
Operating Margin
-1128.1%
Net Margin
-118.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -124.11% |
| 2026-03-31 | -31.49% |
| 2025-12-31 | -161.86% |
| 2025-09-30 | -1222.84% |
| 2024-09-30 | -21760.00% |
| 2024-06-30 | -91050.00% |
| 2024-03-31 | -25096.55% |
| 2023-12-31 | -18554.84% |
| 2023-09-30 | -42737.50% |
| 2023-06-30 | -1587.40% |
| 2018-12-31 | -1638.67% |
| 2016-12-31 | -1135.38% |
| 2016-09-30 | -1679.51% |
| 2016-06-30 | -1678.83% |
| 2016-03-31 | -2663.31% |
| 2015-12-31 | -904.51% |
| 2015-09-30 | -466.99% |
| 2015-06-30 | -1205.07% |
| 2015-03-31 | -1024.61% |
| 2014-12-31 | -2317.00% |
